Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Solid Tumor 1Leukemia 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × ulocuplumab × Clear all
NCT03225716 2024-05-03

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Dana-Farber Cancer Institute

Phase 1 Terminated
13 enrolled 13 charts
Lymphoid

Waldenstrom Macroglobulinemia

NCT02305563 2021-09-16

An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Bristol-Myers Squibb

Phase 1/2 Terminated
70 enrolled 36 charts
Other hematologic neoplasm

Leukemia

NCT02472977 2018-11-01

CXCessoR4

Bristol-Myers Squibb

Phase 1/2 Terminated
61 enrolled 11 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡